Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars)

PrintEmail
January 2024 - 160 Pages - From $2,600
(Excel Data Sheet: $1,500)
Description

The report cover may be different from the image shown.

  • The product will be delivered as a PDF file by Email within 48 business hours upon receiving an order. 
  • To learn more about the report, please Download Free Sample Pages and Download Excel Datasheet Sample. The report will be updated before delivery, so that the most recent historic year is the base year and forecast covers 5-10 years over the base year.
  • Please Contact Us for any question, custom research, and current discount. It is possible now to buy a part of the report such as chapters, sections, data tables or figures.
  • For details about the license types, please refer to our Terms of Service 
Product and Price

By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.

 

Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical trials and approvals for novel biomedicines, escalating healthcare spending, and favorable reimbursement policies.
Highlighted with 43 tables and 86 figures, this 160-page report “Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Europe biopharmaceuticals market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify the Europe biopharmaceuticals market in every aspect of the classification from perspectives of Product Type, Testing Service, Raw Material, Classification, Therapeutic Area and Country.

Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Monoclonal Antibodies
o Anti-cancer Monoclonal Antibodies
o Anti-inflammatory Monoclonal Antibodies
o Other Monoclonal Antibodies
• Recombinant Growth Factors
o Erythropoietin
o Granulocyte Colony Stimulating Factor
• Purified Proteins
o Leukemia Inhibitory Factor (LIF)
o P53 Protein
o P38 Protein
o Other Purified Proteins
• Recombinant Proteins
o Serum Albumin
o Amyloid Protein
o Defensin
o Transferrin
• Recombinant Hormones
o Recombinant Human Growth Hormones
o Recombinant Insulin
o Other Recombinant Hormones
• Vaccines
o Recombinant Vaccines
 Cancer Vaccines
 Malaria Vaccines
 Ebola Vaccines
 Hepatitis Vaccines
 Tetanus Vaccines
 Diphtheria Vaccines
 Cholera Vaccines
 Other Recombinant Vaccines
o Conventional Vaccines
 Polio Vaccines
 Pox Vaccines
 Other Conventional Vaccines
• Recombinant Enzymes
o Enterokinase
o Cyclase
o Caspase
o Cathepsin
• Cell and Gene Therapies
o Allogenic Products
o Autologous Products
o Acellular Products
• Synthetic Immunomodulators
• Other Product Types
o Blood Factors
o Other Products

Based on Testing Service, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Laboratory Testing
• Custom Testing/Customer Proprietary Testing
• Compendial and Multi Compendial Laboratory Testing

By Raw Material, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Formulation Excipients
• Active Pharmaceutical Ingredients (API)
• Other Materials

By Classification, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Innovative Biopharmaceuticals
• Biogenerics and Biosimilars

By Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Oncology
• Inflammatory and Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders
• Cardiovascular Diseases
• Neurological Diseases
• Other Therapeutic Areas

Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Netherlands
• Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2023-2033. The breakdown of national markets by Product Type and Therapeutic Area over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 26
2.1.3 Impact of Russia-Ukraine Conflict 28
2.1.4 Impact of Israel-Palestine War 30
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 40
2.4 Emerging Opportunities and Market Trends 43
2.5 Porter’s Fiver Forces Analysis 47
3 Segmentation of Europe Market by Product Type 51
3.1 Market Overview by Product Type 51
3.2 Monoclonal Antibodies 53
3.2.1 Anti-cancer Monoclonal Antibodies 54
3.2.2 Anti-inflammatory Monoclonal Antibodies 55
3.2.3 Other Monoclonal Antibodies 56
3.3 Recombinant Growth Factors 57
3.3.1 Erythropoietin 58
3.3.2 Granulocyte Colony Stimulating Factor 59
3.4 Purified Proteins 60
3.4.1 Leukemia Inhibitory Factor (LIF) 61
3.4.2 P53 Protein 62
3.4.3 P38 Protein 63
3.4.4 Other Purified Proteins 64
3.5 Recombinant Proteins 65
3.5.1 Serum Albumin 66
3.5.2 Amyloid Protein 67
3.5.3 Defensin 68
3.5.4 Transferrin 69
3.6 Recombinant Hormones 70
3.6.1 Recombinant Human Growth Hormones 71
3.6.2 Recombinant Insulin 73
3.6.3 Other Recombinant Hormones 74
3.7 Vaccines 75
3.7.1 Recombinant Vaccines 76
3.7.2 Conventional Vaccines 78
3.8 Recombinant Enzymes 79
3.8.1 Enterokinase 80
3.8.2 Cyclase 81
3.8.3 Caspase 82
3.8.4 Cathepsin 83
3.9 Cell and Gene Therapies 84
3.9.1 Allogenic Products 85
3.9.2 Autologous Products 86
3.9.3 Acellular Products 87
3.10 Synthetic Immunomodulators 88
3.11 Other Product Types 89
3.11.1 Blood Factors 90
3.11.2 Other Products 91
4 Segmentation of Europe Market by Testing Service 92
4.1 Market Overview by Testing Service 92
4.2 Laboratory Testing 94
4.3 Custom Testing/Customer Proprietary Testing 95
4.4 Compendial and Multi Compendial Laboratory Testing 96
5 Segmentation of Europe Market by Raw Material 97
5.1 Market Overview by Raw Material 97
5.2 Formulation Excipients 99
5.3 Active Pharmaceutical Ingredients (API) 100
5.4 Other Materials 101
6 Segmentation of Europe Market by Classification 102
6.1 Market Overview by Classification 102
6.2 Innovative Biopharmaceuticals 104
6.3 Biogenerics and Biosimilars 105
7 Segmentation of Europe Market by Therapeutic Area 106
7.1 Market Overview by Therapeutic Area 106
7.2 Oncology 108
7.3 Inflammatory and Infectious Diseases 109
7.4 Autoimmune Disorders 110
7.5 Metabolic Disorders 111
7.6 Hormonal Disorders 112
7.7 Cardiovascular Diseases 113
7.8 Neurological Diseases 114
7.9 Other Therapeutic Areas 115
8 European Market 2023-2033 by Country 116
8.1 Overview of European Market 116
8.2 Germany 119
8.3 U.K. 121
8.4 France 123
8.5 Spain 125
8.6 Italy 127
8.7 Netherlands 129
8.8 Rest of European Market 131
9 Competitive Landscape 133
9.1 Overview of Key Vendors 133
9.2 New Product Launch, Partnership, Investment, and M&A 137
9.3 Company Profiles 138
Abbott Laboratories 138
Amgen Inc. 140
Astrazeneca PLC 141
Bayer AG 142
Biogen Inc. 143
Bristol-myers Squibb Company (BMS) 144
Eli Lilly and Company 145
F. Hoffmann-La Roche Ltd. 146
Glaxosmithkline PLC 147
Johnson & Johnson 148
Merck & Co. Inc. 149
Novartis Ag 150
Novo Nordisk As 151
Pfizer Inc. 152
Sanofi Sa 153
Sharp Packaging Services 154
Sun Pharmaceutical Industries Ltd. 155
Takeda Pharmaceutical Company Limited 156
Thermo Fisher Scientific Inc. 157
Vertex Pharmaceuticals 158
WuXi AppTec 159
RELATED REPORTS 160

List of Tables:

Table 1. Snapshot of Europe Biopharmaceuticals Market in Balanced Perspective, 2023-2033 19
Table 2. World Economic Outlook, 2024-2036 23
Table 3. World Economic Outlook, 2022-2024 25
Table 4. Scenarios for Economic Impact of Ukraine Crisis 29
Table 5. Scenarios for Economic Impact of Israel-Palestine War 30
Table 6. World Health Spending by Region, $ bn, 2013-2020 35
Table 7. Total Number of Registered Clinical Studies Worldwide, 2010-2021 36
Table 8. Worldwide Number of New Cancer by Type, 2020 37
Table 9. Main Product Trends and Market Opportunities in Europe Biopharmaceuticals Market 43
Table 10. Europe Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 51
Table 11. Europe Biopharmaceuticals Market: Monoclonal Antibodies by Type, 2023-2033, $ mn 53
Table 12. Europe Biopharmaceuticals Market: Recombinant Growth Factor by Type, 2023-2033, $ mn 57
Table 13. Europe Biopharmaceuticals Market: Purified Proteins by Type, 2023-2033, $ mn 60
Table 14. Europe Biopharmaceuticals Market: Recombinant Proteins by Type, 2023-2033, $ mn 65
Table 15. Europe Biopharmaceuticals Market: Recombinant Hormones by Type, 2023-2033, $ mn 70
Table 16. Selected Drugs for COVID-19 Treatment in Development, Nov 2022 72
Table 17. Europe Biopharmaceuticals Market: Vaccines by Type, 2023-2033, $ mn 75
Table 18. Europe Biopharmaceuticals Market: Recombinant Vaccines by Type, 2023-2033, $ mn 77
Table 19. Europe Biopharmaceuticals Market: Conventional Vaccines by Type, 2023-2033, $ mn 78
Table 20. Europe Biopharmaceuticals Market: Recombinant Enzymes by Type, 2023-2033, $ mn 79
Table 21. Europe Biopharmaceuticals Market: Cell and Gene Therapies by Type, 2023-2033, $ mn 84
Table 22. Europe Biopharmaceuticals Market: Other Product Types by Type, 2023-2033, $ mn 89
Table 23. Europe Biopharmaceuticals Market by Testing Service, 2023-2033, $ mn 92
Table 24. Europe Biopharmaceuticals Market by Raw Material, 2023-2033, $ mn 97
Table 25. Europe Biopharmaceuticals Market by Classification, 2023-2033, $ mn 102
Table 26. Europe Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 106
Table 27. Europe Biopharmaceuticals Market by Country, 2023-2033, $ mn 118
Table 28. Germany Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 120
Table 29. Germany Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 120
Table 30. U.K. Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 122
Table 31. U.K. Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 122
Table 32. France Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 124
Table 33. France Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 124
Table 34. Spain Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 126
Table 35. Spain Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 126
Table 36. Italy Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 128
Table 37. Italy Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 128
Table 38. Netherlands Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 130
Table 39. Netherlands Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 130
Table 40. Biopharmaceuticals Market in Rest of Europe by Country, 2023-2033, $ mn 132
Table 41. Abbott Laboratories: Company Snapshot 138
Table 42. Abbott Laboratories: Business Segmentation 139
Table 43. Abbott Laboratories: Product Portfolio 139

 

 

List of Figures:

Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2023-2033 18
Figure 4. Europe Biopharmaceuticals Market, 2023-2033, $ mn 21
Figure 5. Impact of COVID-19 on Business 26
Figure 6. Primary Drivers and Impact Factors of Europe Biopharmaceuticals Market 31
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 34
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 34
Figure 9. Worldwide Novel Active Substances (NASs) Launches by Therapeutic Area, 2013-2022 35
Figure 10. Primary Restraints and Impact Factors of Europe Biopharmaceuticals Market 40
Figure 11. Investment Opportunity Analysis 44
Figure 12. Porter’s Fiver Forces Analysis of Europe Biopharmaceuticals Market 47
Figure 13. Breakdown of Europe Biopharmaceuticals Market by Product Type, 2023-2033, % of Revenue 52
Figure 14. Europe Addressable Market Cap in 2024-2033 by Product Type, Value ($ mn) and Share (%) 52
Figure 15. Europe Biopharmaceuticals Market by Product Type: Monoclonal Antibodies, 2023-2033, $ mn 53
Figure 16. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Anti-cancer Monoclonal Antibodies, 2023-2033, $ mn 54
Figure 17. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Anti-inflammatory Monoclonal Antibodies, 2023-2033, $ mn 55
Figure 18. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Other Monoclonal Antibodies, 2023-2033, $ mn 56
Figure 19. Europe Biopharmaceuticals Market by Product Type: Recombinant Growth Factors, 2023-2033, $ mn 57
Figure 20. Europe Biopharmaceuticals Market by Recombinant Growth Factor: Erythropoietin, 2023-2033, $ mn 58
Figure 21. Europe Biopharmaceuticals Market by Recombinant Growth Factor: Granulocyte Colony Stimulating Factor, 2023-2033, $ mn 59
Figure 22. Europe Biopharmaceuticals Market by Product Type: Purified Proteins, 2023-2033, $ mn 60
Figure 23. Europe Biopharmaceuticals Market by Purified Proteins: Leukemia Inhibitory Factor (LIF), 2023-2033, $ mn 61
Figure 24. Europe Biopharmaceuticals Market by Purified Proteins: P53 Protein, 2023-2033, $ mn 62
Figure 25. Europe Biopharmaceuticals Market by Purified Proteins: P38 Protein, 2023-2033, $ mn 63
Figure 26. Europe Biopharmaceuticals Market by Purified Proteins: Other Purified Proteins, 2023-2033, $ mn 64
Figure 27. Europe Biopharmaceuticals Market by Product Type: Recombinant Proteins, 2023-2033, $ mn 65
Figure 28. Europe Biopharmaceuticals Market by Recombinant Proteins: Serum Albumin, 2023-2033, $ mn 66
Figure 29. Europe Biopharmaceuticals Market by Recombinant Proteins: Amyloid Protein, 2023-2033, $ mn 67
Figure 30. Europe Biopharmaceuticals Market by Recombinant Proteins: Defensin, 2023-2033, $ mn 68
Figure 31. Europe Biopharmaceuticals Market by Recombinant Proteins: Transferrin, 2023-2033, $ mn 69
Figure 32. Europe Biopharmaceuticals Market by Product Type: Recombinant Hormones, 2023-2033, $ mn 70
Figure 33. Europe Biopharmaceuticals Market by Recombinant Hormones: Recombinant Human Growth Hormones, 2023-2033, $ mn 71
Figure 34. Europe Biopharmaceuticals Market by Recombinant Hormones: Recombinant Insulin, 2023-2033, $ mn 73
Figure 35. Europe Biopharmaceuticals Market by Recombinant Hormones: Other Recombinant Hormones, 2023-2033, $ mn 74
Figure 36. Europe Biopharmaceuticals Market by Product Type: Vaccines, 2023-2033, $ mn 75
Figure 37. Europe Biopharmaceuticals Market by Vaccines: Recombinant Vaccines, 2023-2033, $ mn 76
Figure 38. Europe Biopharmaceuticals Market by Vaccines: Conventional Vaccines, 2023-2033, $ mn 78
Figure 39. Europe Biopharmaceuticals Market by Product Type: Recombinant Enzymes, 2023-2033, $ mn 79
Figure 40. Europe Biopharmaceuticals Market by Recombinant Enzymes: Enterokinase, 2023-2033, $ mn 80
Figure 41. Europe Biopharmaceuticals Market by Recombinant Enzymes: Cyclase, 2023-2033, $ mn 81
Figure 42. Europe Biopharmaceuticals Market by Recombinant Enzymes: Caspase, 2023-2033, $ mn 82
Figure 43. Europe Biopharmaceuticals Market by Recombinant Enzymes: Cathepsin, 2023-2033, $ mn 83
Figure 44. Europe Biopharmaceuticals Market by Product Type: Cell and Gene Therapies, 2023-2033, $ mn 84
Figure 45. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Allogenic Products, 2023-2033, $ mn 85
Figure 46. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Autologous Products, 2023-2033, $ mn 86
Figure 47. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Acellular Products, 2023-2033, $ mn 87
Figure 48. Europe Biopharmaceuticals Market by Product Type: Synthetic Immunomodulators, 2023-2033, $ mn 88
Figure 49. Europe Biopharmaceuticals Market by Product Type: Other Product Types, 2023-2033, $ mn 89
Figure 50. Europe Biopharmaceuticals Market by Other Product Types: Blood Factors, 2023-2033, $ mn 90
Figure 51. Europe Biopharmaceuticals Market by Other Product Types: Other Products, 2023-2033, $ mn 91
Figure 52. Breakdown of Europe Biopharmaceuticals Market by Testing Service, 2023-2033, % of Sales Revenue 93
Figure 53. Europe Addressable Market Cap in 2024-2033 by Testing Service, Value ($ mn) and Share (%) 93
Figure 54. Europe Biopharmaceuticals Market by Testing Service: Laboratory Testing, 2023-2033, $ mn 94
Figure 55. Europe Biopharmaceuticals Market by Testing Service: Custom Testing/Customer Proprietary Testing, 2023-2033, $ mn 95
Figure 56. Europe Biopharmaceuticals Market by Testing Service: Compendial and Multi Compendial Laboratory Testing, 2023-2033, $ mn 96
Figure 57. Breakdown of Europe Biopharmaceuticals Market by Raw Material, 2023-2033, % of Sales Revenue 98
Figure 58. Europe Addressable Market Cap in 2024-2033 by Raw Material, Value ($ mn) and Share (%) 98
Figure 59. Europe Biopharmaceuticals Market by Raw Material: Formulation Excipients, 2023-2033, $ mn 99
Figure 60. Europe Biopharmaceuticals Market by Raw Material: Active Pharmaceutical Ingredients (API), 2023-2033, $ mn 100
Figure 61. Europe Biopharmaceuticals Market by Raw Material: Other Materials, 2023-2033, $ mn 101
Figure 62. Breakdown of Europe Biopharmaceuticals Market by Classification, 2023-2033, % of Revenue 103
Figure 63. Europe Addressable Market Cap in 2024-2033 by Classification, Value ($ mn) and Share (%) 103
Figure 64. Europe Biopharmaceuticals Market by Classification: Innovative Biopharmaceuticals, 2023-2033, $ mn 104
Figure 65. Europe Biopharmaceuticals Market by Classification: Biogenerics and Biosimilars, 2023-2033, $ mn 105
Figure 66. Breakdown of Europe Biopharmaceuticals Market by Therapeutic Area, 2023-2033, % of Revenue 107
Figure 67. Europe Addressable Market Cap in 2024-2033 by Therapeutic Area, Value ($ mn) and Share (%) 107
Figure 68. Europe Biopharmaceuticals Market by Therapeutic Area: Oncology, 2023-2033, $ mn 108
Figure 69. Europe Biopharmaceuticals Market by Therapeutic Area: Inflammatory and Infectious Diseases, 2023-2033, $ mn 109
Figure 70. Europe Biopharmaceuticals Market by Therapeutic Area: Autoimmune Disorders, 2023-2033, $ mn 110
Figure 71. Europe Biopharmaceuticals Market by Therapeutic Area: Metabolic Disorders, 2023-2033, $ mn 111
Figure 72. Europe Biopharmaceuticals Market by Therapeutic Area: Hormonal Disorders, 2023-2033, $ mn 112
Figure 73. Europe Biopharmaceuticals Market by Therapeutic Area: Cardiovascular Diseases, 2023-2033, $ mn 113
Figure 74. Europe Biopharmaceuticals Market by Therapeutic Area: Neurological Diseases, 2023-2033, $ mn 114
Figure 75. Europe Biopharmaceuticals Market by Therapeutic Area: Other Therapeutic Areas, 2023-2033, $ mn 115
Figure 76. Breakdown of European Biopharmaceuticals Market by Country, 2023 and 2033, % of Revenue 117
Figure 77. Contribution to Europe 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%) 118
Figure 78. Biopharmaceuticals Market in Germany, 2023-2033, $ mn 119
Figure 79. Biopharmaceuticals Market in U.K., 2023-2033, $ mn 121
Figure 80. Biopharmaceuticals Market in France, 2023-2033, $ mn 123
Figure 81. Biopharmaceuticals Market in Spain, 2023-2033, $ mn 125
Figure 82. Biopharmaceuticals Market in Italy, 2023-2033, $ mn 127
Figure 83. Biopharmaceuticals Market in Netherlands, 2023-2033, $ mn 129
Figure 84. Biopharmaceuticals Market in Rest of Europe, 2023-2033, $ mn 131
Figure 85. Growth Stage of Europe Biopharmaceuticals Industry over the Forecast Period 133
Figure 86. Worldwide Top Ten Best-selling Biotech Drugs in 2022, $ bn 135

 

Reviews

There are yet no reviews for this product.